May 3, 2026 01:10PM
May 3, 2026 01:10PM
Apr 17, 2026 02:00PM
Apr 17, 2026 02:00PM
Apr 15, 2026 07:00AM
Mar 24, 2026 02:46PM
Dec 8, 2025 07:00AM UCB's fenfluramine meets phase 3 trial goals for rare seizure disorder
Dec 8, 2025 07:00AM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Oct 31, 2025 01:04PM
Oct 29, 2025 07:00AM
Oct 14, 2025 07:10AM Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior
Sep 17, 2025 07:00AM
Jun 12, 2025 12:30PM
May 19, 2025 12:30PM
Apr 3, 2025 07:00AM
Mar 19, 2025 07:00AM
Mar 12, 2025 01:54PM
Mar 7, 2025 08:00AM BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Feb 27, 2025 07:00AM
Jan 16, 2025 07:00AM
Dec 6, 2024 12:00PM
Nov 26, 2024 07:00AM
Nov 20, 2024 07:00AM
Nov 14, 2024 12:46PM
Sep 23, 2024 07:00AM UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Jun 24, 2024 07:00AM
Jun 20, 2024 08:00AM
May 23, 2024 07:00AM
Apr 12, 2024 07:00AM
Apr 4, 2024 07:00AM
Feb 28, 2024 07:03AM
Jan 3, 2024 07:00AM ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positiv
Dec 2, 2023 07:00AM
Dec 1, 2023 07:00AM
Nov 14, 2023 07:00AM
Nov 1, 2023 07:00AM
Oct 31, 2023 07:00AM
Oct 18, 2023 07:00AM
Oct 17, 2023 06:34PM UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Oct 13, 2023 12:00PM
Oct 12, 2023 12:20PM
Oct 4, 2023 01:06PM
Jul 21, 2023 07:00AM
Jun 27, 2023 07:00AM
Apr 20, 2023 07:00AM
Apr 17, 2023 07:14AM UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
Mar 18, 2023 02:10PM

322,137 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All